4.5 Article

MultiGML: Multimodal graph machine learning for prediction of adverse drug events

期刊

HELIYON
卷 9, 期 9, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.heliyon.2023.e19441

关键词

Machine learning; Knowledge graph; Adverse event; Graph neural network; Graph attention network; Graph convolutional network

向作者/读者索取更多资源

This study proposes an integrative and explainable multimodal Graph Machine Learning approach (MultiGML) to predict drug-related adverse events and drug target-phenotype associations. MultiGML demonstrates excellent prediction performance and provides in-depth explanations of model predictions.
Adverse drug events constitute a major challenge for the success of clinical trials. Several computational strategies have been suggested to estimate the risk of adverse drug events in preclinical drug development. While these approaches have demonstrated high utility in practice, they are at the same time limited to specific information sources. Thus, many current computational approaches neglect a wealth of information which results from the integration of different data sources, such as biological protein function, gene expression, chemical compound structure, cell-based imaging and others. In this work we propose an integrative and explainable multimodal Graph Machine Learning approach (MultiGML), which fuses knowledge graphs with multiple further data modalities to predict drug related adverse events and general drug targetphenotype associations. MultiGML demonstrates excellent prediction performance compared to alternative algorithms, including various traditional knowledge graph embedding techniques. MultiGML distinguishes itself from alternative techniques by providing in-depth explanations of model predictions, which point towards biological mechanisms associated with predictions of an adverse drug event. Hence, MultiGML could be a versatile tool to support decision making in preclinical drug development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据